- Visibility 598 Views
- Downloads 744 Downloads
- Permissions
- DOI 10.18231/j.ijos.2025.019
-
CrossMark
Evidence-based expert recommendations for the diagnosis and targeted management of osteoporosis
- Author Details:
-
Ram Chaddha
-
BL Prakash
-
Ravi Sauhta
-
Vishal Peshhatiwar
-
Dayanidhi Meher
-
Alpa Singh *
-
Monil Gala
-
Snehal Muchhala
-
Bhavesh Kotak
Ravi Sauhta
Vishal Peshhatiwar
Dayanidhi Meher
Alpa Singh *
Monil Gala
Snehal Muchhala
Bhavesh Kotak
To derive practical, experience-driven clinical insights related to evidence-based statements for diagnosing and managing osteoporosis. The meeting involved in-depth discussions and a review of recent literature and real-world clinical perspectives. A set of 32 evidence-based statements was developed following a literature search of English articles from 2018 to 2023, using keywords such as ‘Osteoporosis’, ‘Diagnosis’, ‘Romosozumab’ and ‘anti-osteoporosis’. Two virtual national meetings were held with 23 experts in Orthopaedics, Rheumatology and Endocrinology. According to the evidence-based recommendation, osteoporosis frequently progresses as a "silent disease," showing no signs until a fracture happens. The risk varies by age, gender and other factors. Screening is recommended for postmenopausal women over 50 years and men over 60 years of age due to their higher risk of bone loss. The dual-energy X-ray absorptiometry scan is the gold standard for diagnosing osteoporosis. It should be repeated every 1-2 years to track bone mineral density (BMD). The Fracture Risk Assessment Tool helps to evaluate the risk of fragility fractures. Bone turnover markers help assess the effectiveness of treatment. Anti-osteoporosis treatments are recommended for those at a high or very high fracture risk. Anti-resorptive therapies are suitable for high-risk patients, whereas anabolic therapies are preferred for very high-risk cases. Romosozumab, a dual-action medication, is effective in postmenopausal women and has been approved for men in Japan and Australia as of December 2024. The ideal candidates for Romosozumab include those with declining BMD, despite anti-resorptive treatment or a high fracture risk.
Keywords: Osteoporosis, Postmenopausal, Dual-energy X-ray absorptiometry, Fracture risk assessment tool, Anabolics, Anti-resorptive, Romosozumab, Denosumab.
References
- Lasaite L, Krasauskiene A. Psychological state, quality of life, and body composition in postmenopausal women with osteoporosis in Lithuania. Arch Osteoporos. 2009;4(1-2):85–90. Chaddha et al / Indian Journal of Orthopaedics Surgery 2025;11(2):86–96 95
- Rashki Kemmak A, Rezapour A, Jahangiri R, Nikjoo S, Farabi H, Soleimanpour S. Economic burden of osteoporosis in the world: a systematic review. Med J Islam Repub Iran. 2020;34:154.
- Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
- Khadilkar AV, Mandlik RM. Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health. 2015;7:841–50.
- Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.
- Saxena Y, Routh S, Mukhopadhaya A. Immunoporosis: role of innate immune cells in osteoporosis. Front Immunol. 2021;12:687037.
- Hertz K, Santy-Tomlinson J, editors. Fragility fracture nursing: holistic care and management of the orthogeriatric patient [Internet]. Cham (CH): Springer; 2018.
- Khinda R, Valecha S, Kumar N, Walia JPS, Singh K, Sethi S, et al. Prevalence and predictors of osteoporosis and osteopenia in postmenopausal women of Punjab, India. Int J Environ Res Public Health. 2022;19(5):2999.
- Manjula S, Kumar KM. Expert opinion on the clinical use of calcium and vitamin D supplements in osteoporosis in Indian settings. Int J Res Orthop. 2024;10(2):364–8.
- Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: a review of treatment options. P T. 2018;43(2):92–
- Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
- Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al. Osteoporosis Canada 2023 Guideline Update Group. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ. 2023;195(39):E1333–48.
- Chen DL, Goldrick A, Greenfield JR. severe symptomatic hypocalcaemia following high-dose oral ibandronate in a patient with prior thyroidectomy and metastatic bone disease. J Endocrinol Metab. 2012;2(2):96–8.
- Laura I, Felicia B, Alexia C, Aude M, Florence B, Murielle S, et al. Which treatment to prevent an imminent fracture? Bone Rep. 2021;15:101105.
- Eatz TA, Chertman L, Levis S, Lagari V. Denosumab-associated hypocalcemia in a patient with chronic kidney disease and Paget's disease. J Clin Transl Endocrinol Case Rep. 2022;24:100115.
- Svendsen OL. Treatment of osteoporosis with denosumab in patients with decreased kidney function. Arch Osteoporos. 2023;18(1):104.
- Aditya S, Rattan A. Sclerostin inhibition: a novel target for the treatment of postmenopausal osteoporosis. J Mid-life Health. 2021;12:267–75.
- CDSCO. List of new drugs (r-DNA origin) approved for import and marketing in India during Jan, 2020 – Jun, 2024 [Internet]. Available from: https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/ 2018/UploadBiologicalrDNA/CT- 18%20Approvals%20Jan,%202020%20-%20July,%202024.pdf.
- Bhadada SK, Chadha M, Sriram U, Pal R, Paul TV, Khadgawat R, et al. The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults. Arch Osteoporos. 2021;16(1):102.
- International Osteoporosis Foundation. Epidemiology [Internet]. Available from: https://www.osteoporosis.foundation/health- professionals/about-osteoporosis/epidemiology.
- Brown JP. Long -term treatment of postmenopausal osteoporosis. Endocrinol Metab (Seoul). 2021;36(3):544–52.
- Bin AS. Approach and assessment of osteoporosis: identifying and managing risk. SFP. 2018;44(3):7–10.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis causes and symptoms. Available from: https://www.niams.nih.gov/health-topics/osteoporosis.
- Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. J Womens Health (Larchmt). 2014;23(7):563–72.
- Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(24):2532–51.
- Royal Osteoporosis Society. Glucocorticoids (“steroids”) and osteoporosis [Internet]. Available from: https://theros.org.uk/media/t1kl1fb5/glucocorticoids-steroids-and- osteoporosis-fact-sheet-august-2017.pdf.
- Gaffney CD, Pagano MJ, Kuker AP, Stember DS, Stahl PJ. Osteoporosis and low bone mineral density in men with testosterone deficiency syndrome. Sex Med Rev. 2015;3(4):298–315.
- Formosa MM, Christou MA, Mäkitie O. Bone fragility and osteoporosis in children and young adults. J Endocrinol Invest. 2024;47(2):285–98.
- Chen M, Gerges M, Raynor WY, Park PSU, Nguyen E, Chan DH et al. State of the art imaging of osteoporosis. Semin Nucl Med. 2024;54(3):415–26.
- Ryu SM, Lee S, Jang M, Koh JM, Bae SJ, Jegal SG, et al. Diagnosis of osteoporotic vertebral compression fractures and fracture level detection using multitask learning with U-Net in lumbar spine lateral radiographs. Comput Struct Biotechnol J. 2023;21:3452–8.
- Ibrahim MO, Kolleri A, Ginawi A. The use of bone density scan in monitoring treatment response in patients diagnosed with osteoporosis: a retrospective cohort study. Int J Rheumatol. 2023;2023:2160346.
- Sucharitpongpan W. The optimal cut-off values of FRAX ® without BMD for predicting osteoporosis fracture risk in the older adults at Nan, Thailand. Osteoporos Sarcopenia. 2024;10(1):11–5.
- Asirvatham AR, Balachandran K, Kannan S, Balasubramaniam SK, Mahadevan S. FRAX ® First-pragmatic approach in resource poor settings. Indian J Endocrinol Metab. 2018;22(6):757–9.
- Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. Int J Womens Dermatol. 2021;7(5Part A):545–51.
- Santos Monteiro S, da Silva Santos T, Fonseca L, Dores J. Evaluation of usage of a fracture risk assessment by FRAX ® tool in adults with type 2 diabetes mellitus. Cureus. 2023;15(2):e35205.
- Li N, Jørgensen NR, Reginster JY, Hiligsmann M. The impact of bone turnover marker on medication adherence and the health economics-related consequences. Expert Rev Pharmacoecon Outcomes Res. 2024;24(7):787–90.
- Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8(7):379–89.
- Park SY, Ahn SH, Yoo JI, Chung YJ, Jeon YK, Yoon BH, et al. Position statement on the use of bone turnover markers for osteoporosis treatment. J Bone Metab. 2019;26(4):213–24.
- Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.
- Albrecht BM, Stalling I, Foettinger L, Recke C, Bammann K. Adherence to lifestyle recommendations for bone health in older adults with and without osteoporosis: cross-sectional results of the OUTDOOR ACTIVE study. Nutrients. 2022;14(12):2463.
- Farrah Z, Jawad AS. Optimising the management of osteoporosis. Clin Med (Lond). 2020;20(5):e196–e201.
- LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–102.
- Cormick G, Belizán JM. Calcium intake and health. Nutrients. 2019;11(7):1606.
- Singh V, Misra AK, Singh M, Midha NK, Kumar B, Ambwani S, et al. An open-label, randomized, 10 weeks prospective study on the 96 Chaddha et al. / Indian Journal of Orthopaedics Surgery 2025;11(2):86–96 efficacy of vitamin D (daily low dose and weekly high dose) in vitamin D deficient patients. J Family Med Prim Care. 2019;8(6):1958–63.
- Meeta M, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S. Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations – update 2019-2020. J Midlife Health. 2020;11(2):96–112
- Mukherjee AN, Londhe S, Prasad PVS, Shetty N, Shetty S, Kumar N. Specific collagen peptides in osteoporosis management: unraveling therapeutic potential through expert perspectives and scientific insights. Int J Orthop Sci. 2024;10(1):165–71.
- Moreira CA, Ferreira CEDS, Madeira M, Silva BCC, Maeda SS, Batista MC, et al. Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC). Arch Endocrinol Metab. 2020;64(4):462–78.
- Hsu S, Vervloet MG, de Boer IH. Vitamin D in CKD: an unfinished story. Am J Kidney Dis. 2023;82(5):512–4.
- Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101(6):2313–24.
- Dimai HP, Fahrleitner-Pammer A. Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol. 2022;36(3):101780.
- Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3):dgaa048.
- Tai TW, Chen HY, Shih CA, Huang CF, McCloskey E, Lee JK, et al. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporos Sarcopenia. 2024;10(1):3–10.
- Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab. 2022;66(5):707–16.
- Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32(2):198-202.
- Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther. 2017;11:1221–31.
- Soen S, Wang A, Hamaya E, Chien HC, Lin TC. Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021. J Bone Miner Metab. 2024;42(6):653–67.
- Australian Public Assessment Report for Romosozumab [Internet]. [Updated January 2020]. Available from: https://www.tga.gov.au/sites/default/files/auspar-romosozumab-
- pdf.
- Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, et al. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep. 2021;14:101068.
- Krupa KN, Parmar M, Delo LF. Romosozumab. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing. [Updated 2024 July]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585139/.
- Stokar J, Szalat A. cardiovascular safety of Romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab. 2025;110(3):e861–7.
- Cheng SH, Chu W, Chou WH, Chu WC, Kang YN. Cardiovascular safety of romosozumab compared to commonly used anti- osteoporosis medications in postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Drug Saf. 2025;48(1):7–23.
- Ferrari SL. Osteoporosis: Romosozumab to rebuild the foundations of bone strength. Nat Rev Rheumatol. 2018;14(3):128.
- Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–94.
- Möckel L, Bartneck M, Möckel C. Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporos Sarcopenia. 2020;6(1):20–6.
- Tian A, Jia H, Zhu S, Lu B, Li Y, Ma J, et al. Romosozumab versus Teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop Surg. 2021;13(7):1941–50.
- Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. 2022;37(8):1437–45.
- Mok CC, Chan KL, Tse SM, Chen SPL, Tan KCB, Ma WH. Romosozumab versus denosumab in long- term users of glucocorticoids: a pilot randomized controlled trial. J Intern Med. 2024;296(6):481–94.
- Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta- analysis. Drug Des Devel Ther. 2019;13:2843–52.
- Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022;39(1):58–74.
- Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–35.
- Tsai JN, Lee H, David NL, Eastell R, Leder BZ. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019;7(10):767–75.
- Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–700.
- Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–55.
- Kostenuik PJ, Binkley N, Anderson PA. Advances in osteoporosis therapy: Focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Curr Osteoporos Rep. 2023;21(4):386–400.
- Pitropakis I. The action of anti-resorptive drugs on the survival of total knee and hip arthroplasty. J Res Prac Musculoskelet Syst. 2021;5(1):1–7.
- Russow G, Jahn D, Appelt J, Märdian S, Tsitsilonis S, Keller J. Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci. 2018;20(1):83.